Herceptin Hylecta is a prescription drug approved by the Food and Drug Administration (FDA) as an adjuvant treatment for metastatic breast cancer in cases where tumors overexpress the HER2 protein and one or more chemotherapy regimens have been tried. Herceptin Hylecta is a combination drug composed of Trastuzumab and Hyaluronidase. Herceptin Hylecta may be prescribed alone or in combination with a course of chemotherapy.
In about 25 percent of breast cancers, there is a genetic variation that causes tumor cells to produce extra receptors for a growth factor. This gene, known as human epidermal growth factor receptor 2 (HER2), causes the cancer to grow more aggressively. Trastuzumab is a member of a class of drugs called biologics. Trastuzumab is a monoclonal antibody designed to turn off the HER2 gene. Hyaluronidase is a type of enzyme called an endoglycosidase. Hyaluronidase is believed to work by increasing the absorption of Trastuzumab. Herceptin Hylecta is believed to work by reducing the amount of growth factor receptors on cancer cells, thereby slowing the growth of tumors.
How do I take it?
Herceptin Hylecta is administered subcutaneously once every three weeks by a healthcare professional.
Herceptin Hylecta is available in a vial.
For those being treated after surgery, common adverse reactions for Herceptin Hylecta are fatigue, joint pain, diarrhea, injection site reaction, upper respiratory tract infection, rash, myalgia, nausea, headache, edema, flushing, fever, cough, and pain in extremities.
For those being treated for metastatic breast cancer, side effects include fever, chills, headache, infection, congestive heart failure, insomnia, cough, and rash.
Rare but serious side effects listed for Herceptin Hylecta can include heart failure, lung damage, fetal harm, and severe infusion reactions.
For more details about this treatment, visit:
Herceptin Hylecta – Genentech